We are developing proprietary drugs to treat neurological diseases. Our lead product candidate, SER-252 for advanced Parkinsons Disease, is anticipated to enter clinical trials in the fourth quarter of 2025. Our follow-on candidate, SER-270 for Tardive Dyskinesia, is anticipated to enter IND enabling studies in the fourth quarter of 2025.

​

Our current small molecule discovery and development work includes a focus on unlocking the potential of molecules across a range of CNS indications and beyond.

​

Our POZ Platform™ partners are at the forefront in advancing novel RNA medicines in vaccine immunology, cancer immunoRX, and gene therapy.